Quest Diagnostics Incorporated
DGX evidence brief
What we can confirm
- BioSniper Score:
- 5.0 / 10
- Market Cap:
- $27.27B
- Next Catalyst:
- Earnings · Oct 22, 2026
What it means
What to watch
Prepared research question
What matters most for DGX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · DGX
Quest Diagnostics is a leading provider of diagnostic testing services, with a focus on innovation and customer-centric offerings, reporting strong financial performance in 2025.
Key risk: Forward-looking uncertainties
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 1 catalyst for Quest Diagnostics Incorporated.
Quest Diagnostics is a leading provider of diagnostic testing services, with a focus on innovation and customer-centric offerings, reporting strong financial performance in 2025.
- Reported net revenues of $11.04BB for 2025 [sec · filed 2026-04-06].
- Operating income as a percentage of net revenues was 14.1% in 2025 [sec · filed 2026-04-06].
- Cash provided by operations was $1.89BB in 2025 [sec · filed 2026-04-06].
- As of 2026-06-30, cash & equivalents were $626.0M, total revenue $3,043.0M, net income $320.0M, and shareholders' equity $7,516.0M [latest reported financials].
- Diluted earnings per share (EPS) was $8.75 in 2025 [sec · filed 2026-04-06].
What works
- Strong revenue growth of almost 12% in 2025, indicating robust business expansion [sec · filed 2026-04-06].
- Significant cash flow generation, with cash provided by operations of $1.89BB in 2025 [sec · filed 2026-04-06].
- Disciplined capital allocation and increased returns to stockholders in 2025 [sec · filed 2026-04-06].
- Substantial progress in innovation and customer-centric offerings [sec · filed 2026-04-06].
What to weigh
- Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from plans [sec_mda · as of 2026-04-22].
- The company may need access to additional financing to fund normal business operations, acquisitions, and satisfy upcoming debt maturities [sec_mda · as of 2026-04-22].
From the filings
Quoted directly from source documents.
2025 revenue growth and financial performance
“We produced almost 12% revenue growth, expanded profitability, generated significant cash flow, and made substantial progress in innovation and customer-centric offerings.”
SEC filings · April 6, 2026
Forward-looking statements risk
“These forward-looking statements are based on our current plans and expectations and are subject to a number of risks and uncertainties that could cause our plans and expectations, including actual results, to differ materially from”
SEC MD&A · April 22, 2026
Catalyst timeline
- 2026-10-22 · Earnings — Earnings: Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026 — The company will report its third quarter financial performance, providing insight into ongoing revenue and profitability trends.
Risks & what to watch (2)›
Key risks
- Forward-looking uncertainties — Actual results may differ materially from plans due to risks and uncertainties [sec_mda · as of 2026-04-22].
- Financing needs — May require additional financing for operations, acquisitions, and debt maturities [sec_mda · as of 2026-04-22].
What to watch
- Third quarter financial results to be released on October 22, 2026 [upcoming catalysts].
- Ability to maintain revenue growth and profitability trends from 2025 [sec · filed 2026-04-06].
- Execution of strategic priorities and capital allocation discipline [sec · filed 2026-04-06].
Sources: Competitor trials · SEC filings · SEC MD&A · Generated October 10, 2026 · How we verify sources →
Run Quest Diagnostics Incorporated through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Quest Diagnostics Incorporated facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 1.25 · 1% dilution
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~8d
0 buys · 3 sells (180d)
Catalysts
Financials
Short Interest
as of May 10, 2026- % of float
- 3.2%
- Days to cover
- 4.1
- Shares short
- 3,551,568
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
DGX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Quest Diagnostics Incorporated?
Quest Diagnostics is a leading provider of diagnostic testing services, with a focus on innovation and customer-centric offerings, reporting strong financial performance in 2025.
What is Quest Diagnostics Incorporated's next catalyst?
Quest Diagnostics Incorporated's next tracked catalyst is a Earnings event — "Earnings: Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026" — expected October 22, 2026.
Who is the CEO of Quest Diagnostics Incorporated?
Mr. James E. Davis is the chief executive officer of Quest Diagnostics Incorporated (DGX).
Where is Quest Diagnostics Incorporated headquartered?
Quest Diagnostics Incorporated (DGX) is headquartered in Secaucus, NJ, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.